Aims Heart failure (HF) often coexists with chronic kidney disease (CKD), impacting prognosis. This study aims to evaluate ...

Heart failure with preserved ejection fraction (HFpEF) is a type of heart failure that affects the left side of the heart. It occurs when the lower left chamber of the heart, called the left ventricle ...

Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of patients with heart failure with left ventricular ejection fraction (LVEF) ...

Heart failure management includes the four pillars (quad therapy) in HFrEF and HFpEF, plus advances in heart transplantation ...

Finerenone reduced the composite of total first and recurrent heart failure (HF) events (hospitalizations for HF or urgent HF visits) and cardiovascular death in patients with HF and mildly reduced or ...

Finerenone was associated with a 16% reduction for the primary composite endpoint of cardiovascular death and total HF events compared with placebo. The Food and Drug Administration (FDA) has accepted ...

The role of ACE inhibitors in the management of HFPEF is less significant compared with their role in the management of heart failure with left ventricular systolic dysfunction. For patients with ...